Prevention of osteoporosis and osteoporotic fractures in postmenopausal women: recommendation statement from the Canadian Task Force on Preventive Health Care.
Cheung
Angela M
AM
Women's Health Program, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Feig
Denice S
DS
Kapral
Moira
M
Diaz-Granados
Natalia
N
Dodin
Sylvie
S
D000368:Aged; D015519:Bone Density; D004164:Diphosphonates / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D005260:Female; D050723:Fractures, Bone / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000150:complications* / Q000517:prevention & control*; D017698:Postmenopause; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D012307:Risk Factors; D016387:Women's Health
D004164:Diphosphonates; D004965:Estrogen Antagonists; D020849:Raloxifene Hydrochloride